Australia Infant Phototherapy Device Market Forecast 2026-2034

Australia Infant Phototherapy Device Market Outlook & Revenue Forecast (2026-2034)

Australia Infant Phototherapy Device Market is expected to reach US$ 744.53 Million by 2034 from US$ 432.54 Million in 2025, with a CAGR of 6.22% from 2026 to 2034. Australia's infant phototherapy device market is growing due to increasing preterm births, rising neonatal jaundice incidence, expanding neonatal intensive care infrastructure, government investment in maternal and child healthcare, adoption of LED phototherapy technology, and growing emphasis on early diagnosis and effective neonatal care.

Australia Infant Phototherapy Device Industry at a Glance

An infant phototherapy device is a medical system used to treat neonatal jaundice, a common condition caused by elevated bilirubin levels in newborns. The device emits blue light at specific wavelengths, converting bilirubin into water-soluble compounds that can be naturally eliminated without invasive treatment. Modern phototherapy systems use energy-efficient LED technology, providing uniform light intensity while generating minimal heat to improve infant safety and comfort. These devices are widely used in neonatal intensive care units (NICUs), maternity hospitals, and pediatric clinics. Early phototherapy treatment helps prevent severe complications such as kernicterus, reducing hospital stays and improving neonatal health outcomes.

Australia's infant phototherapy device market is expanding steadily due to increasing awareness of neonatal jaundice, rising premature birth rates, and continued investments in maternal and neonatal healthcare services. Hospitals are replacing conventional fluorescent systems with advanced LED phototherapy devices that provide higher treatment efficiency, lower energy consumption, and improved infant safety. Government initiatives supporting neonatal intensive care infrastructure and universal newborn screening programs are encouraging earlier diagnosis and timely intervention. Growing demand for portable and fiber-optic phototherapy systems, combined with technological innovations that enable continuous monitoring and better clinical outcomes, is further driving adoption across public hospitals, private healthcare facilities, and specialized neonatal care units.

Key Forces Accelerating Australia Infant Phototherapy Device Market

Increasing Incidence of Neonatal Jaundice and Preterm Births Expands Treatment Demand

Australia continues to experience consistent demand for infant phototherapy devices as neonatal jaundice remains one of the most common conditions requiring treatment in newborns, particularly among premature and low-birth-weight infants. Healthcare providers emphasize early bilirubin screening and prompt phototherapy intervention to prevent severe neurological complications such as kernicterus. Growing awareness among clinicians and parents regarding timely diagnosis has increased the adoption of advanced LED phototherapy systems across neonatal intensive care units (NICUs) and maternity hospitals. The country's strong maternal and child healthcare programs further support widespread newborn screening and standardized treatment protocols. In addition, hospitals are increasingly replacing conventional fluorescent phototherapy equipment with energy-efficient LED systems that provide uniform irradiance, lower heat generation, and shorter treatment duration, improving both clinical outcomes and patient safety.

In July 2025, Koala Medical Pty Ltd introduced its Overhead Infant Phototherapy Unit in Australia following inclusion in the Therapeutic Goods Administration (TGA) register, expanding access to advanced LED phototherapy technology for neonatal care.

Technological Advancements in LED Phototherapy Improve Clinical Outcomes

Technological innovation is transforming Australia's infant phototherapy device market as hospitals increasingly adopt advanced LED-based systems over conventional fluorescent equipment. Modern phototherapy devices provide higher irradiance, uniform light distribution, lower heat generation, and significantly longer operational life, improving both treatment effectiveness and neonatal safety. Portable, fiber-optic, and blanket-based phototherapy systems are also gaining popularity because they enable family-centered care by allowing parents to hold and feed infants during treatment. Integration with neonatal monitoring systems, touchscreen controls, adjustable irradiance, and energy-efficient operation further enhances workflow in neonatal intensive care units (NICUs). As hospitals continue modernizing neonatal care infrastructure, demand for technologically advanced phototherapy systems is expected to rise across Australia's public and private healthcare sectors.

In March 2026, Clifford Hallam Healthcare Pty Ltd (Paragon Care Australia) secured Therapeutic Goods Administration (TGA) inclusion for a Blanket/Pad Infant Phototherapy Unit manufactured by Natus Medical Denmark ApS, expanding the availability of advanced fiber-optic phototherapy solutions for neonatal jaundice treatment in Australia.

Regulatory Approvals and Advanced LED Technologies Strengthen Market Growth

Australia's infant phototherapy device market is benefiting from continuous regulatory approvals and the adoption of advanced LED technologies that improve neonatal jaundice treatment. Hospitals are increasingly investing in phototherapy systems offering high irradiance, uniform light distribution, reduced heat emission, and lower energy consumption. Modern devices also feature integrated irradiance monitoring, adjustable intensity, electronic documentation, and compatibility with neonatal warmers and incubators, enhancing clinical efficiency and patient safety. The ongoing replacement of conventional fluorescent units with LED-based systems, together with government investments in neonatal intensive care infrastructure, is accelerating market expansion. As healthcare providers prioritize evidence-based neonatal care and shorter treatment durations, demand for technologically advanced phototherapy devices is expected to increase steadily across Australia's public and private healthcare facilities.

In February 2026, Bryta Holdings Pty Ltd received Therapeutic Goods Administration (TGA) approval for its Visible-light Neurological Phototherapy Unit, expanding Australia's regulated phototherapy device portfolio and supporting broader adoption of advanced light-based therapeutic technologies.

Market Headwinds Facing Australia Infant Phototherapy Device Sector

High Procurement Costs and Budget Constraints in Public Healthcare

Despite Australia's well-developed healthcare system, the high acquisition and maintenance costs of advanced infant phototherapy devices remain a challenge, particularly for smaller regional hospitals and community healthcare facilities. Modern LED phototherapy systems with integrated irradiance monitoring, touchscreen controls, and portable configurations require significant capital investment compared with conventional fluorescent units. Additional costs associated with staff training, equipment calibration, preventive maintenance, and periodic upgrades further increase the financial burden on healthcare providers. Budget limitations may delay equipment replacement cycles, causing some facilities to continue using older systems with lower treatment efficiency. Balancing technology adoption with healthcare expenditure remains an important consideration for hospitals seeking to improve neonatal care while maintaining cost-effective resource allocation.

Limited Access to Specialized Neonatal Care in Remote Areas

Although Australia has an extensive healthcare network, access to specialized neonatal services remains uneven across rural and remote regions. Many smaller hospitals lack advanced neonatal intensive care units (NICUs) and specialist neonatologists, requiring newborns with severe jaundice to be transferred to metropolitan hospitals for treatment. These transfers can increase healthcare costs, delay therapy initiation, and place emotional and logistical burdens on families. Workforce shortages, geographic isolation, and limited availability of advanced phototherapy equipment further contribute to disparities in neonatal care. Expanding telehealth support, strengthening regional maternity services, and increasing investment in portable LED phototherapy systems can help improve timely treatment access and reduce healthcare inequalities across remote communities.

New South Wales: Advancing Neonatal Care Through Smart Phototherapy Solutions

New South Wales is a leading market for infant phototherapy devices owing to its extensive network of tertiary hospitals, neonatal intensive care units (NICUs), and well-established maternity services. Healthcare providers are increasingly adopting LED-based phototherapy systems to improve treatment efficiency, reduce energy consumption, and enhance neonatal safety. Rising awareness of neonatal jaundice and routine bilirubin screening are encouraging earlier intervention, supporting demand for advanced phototherapy equipment. Public hospitals continue upgrading neonatal care infrastructure, while private healthcare providers invest in portable and fiber-optic phototherapy solutions. Growing emphasis on evidence-based neonatal care, combined with continuous modernization of hospital facilities, is expected to sustain demand for innovative infant phototherapy devices across metropolitan and regional healthcare settings.

Victoria: Driving Innovation in Infant Jaundice Treatment

Victoria is a significant market for infant phototherapy devices due to its advanced healthcare system, high concentration of specialist children's hospitals, and strong maternal healthcare services. Hospitals are increasingly replacing conventional fluorescent phototherapy units with advanced LED systems that provide greater treatment effectiveness and improved infant comfort. Growing investments in neonatal intensive care facilities, expanding pediatric services, and increasing awareness of early jaundice management are driving market growth. Demand is further supported by the state's emphasis on clinical innovation, digital healthcare integration, and improved neonatal outcomes. Continued modernization of hospital infrastructure and adoption of technologically advanced neonatal equipment are expected to strengthen the infant phototherapy device market throughout Victoria.

Queensland: Expanding Access to Modern Neonatal Phototherapy

Queensland's infant phototherapy device market is expanding due to increasing healthcare investments and the need to provide quality neonatal care across both metropolitan and geographically dispersed communities. Major hospitals are adopting advanced LED phototherapy technologies to improve treatment outcomes for neonatal jaundice while reducing maintenance requirements. The state's large geographic area has also encouraged demand for portable and mobile phototherapy devices that can support regional hospitals and outreach healthcare services. Continuous expansion of neonatal intensive care capabilities, coupled with improved maternal healthcare programs, is supporting market growth. Technological advancements and government efforts to improve access to specialized neonatal care are expected to further drive demand across Queensland.

Western Australia: Strengthening Neonatal Healthcare Across Urban and Remote Communities

Western Australia is witnessing steady growth in the infant phototherapy device market as healthcare providers work to improve neonatal care across its vast geographic region. Large metropolitan hospitals are investing in advanced LED phototherapy equipment, while regional healthcare facilities increasingly utilize compact and mobile systems to enhance access for remote communities. Growing awareness of neonatal jaundice, improvements in maternal and child healthcare services, and continued modernization of neonatal intensive care units are supporting market expansion. The state's focus on reducing healthcare disparities through better access to specialized neonatal treatment is encouraging adoption of efficient phototherapy technologies. Ongoing investment in hospital infrastructure is expected to sustain demand for infant phototherapy devices across Western Australia.

Australia Fluorescent Lamps Market

Australia's fluorescent lamps market for infant phototherapy devices is gradually declining as healthcare facilities transition toward advanced LED-based phototherapy systems. Traditional fluorescent lamps have been widely used for neonatal jaundice treatment because of their established clinical effectiveness and relatively low initial cost. However, they require frequent replacement, generate more heat, consume higher levels of electricity, and deliver less consistent light intensity compared to modern LED alternatives. Hospitals are increasingly replacing fluorescent phototherapy units with energy-efficient LED devices that offer longer operational life, reduced maintenance requirements, and improved treatment outcomes. Although fluorescent systems continue to be used in some healthcare facilities due to existing infrastructure and budget considerations, demand is expected to decline steadily as hospitals modernize neonatal care equipment.

Australia Infant Phototherapy Mobile Device Market

Australia's infant phototherapy mobile device market is expanding as hospitals and neonatal care centers seek flexible treatment solutions that improve clinical workflow and patient comfort. Mobile phototherapy units equipped with LED technology enable caregivers to transport devices easily between neonatal intensive care units (NICUs), maternity wards, and pediatric departments while maintaining effective jaundice treatment. These systems offer adjustable height, compact designs, and energy-efficient operation, making them suitable for facilities with varying patient volumes. Growing emphasis on family-centered neonatal care and space optimization is further supporting demand for portable phototherapy equipment. Continued investments in hospital modernization and technological advancements are expected to drive adoption of mobile infant phototherapy devices across Australia's public and private healthcare sectors.

Australia Infant Phototherapy Hospital Market

Hospitals represent the largest end-user segment for infant phototherapy devices in Australia due to the high volume of neonatal births requiring jaundice screening and treatment. Public and private hospitals, particularly those with neonatal intensive care units (NICUs), are increasingly adopting advanced LED phototherapy systems to improve treatment efficiency, reduce hospitalization time, and enhance infant safety. Continuous upgrades to maternity wards and neonatal departments, combined with standardized clinical guidelines for bilirubin management, are supporting sustained demand for phototherapy equipment. Hospitals also favor integrated phototherapy systems with digital monitoring capabilities that improve clinical decision-making and workflow efficiency. Ongoing investments in neonatal healthcare infrastructure are expected to maintain strong demand for advanced hospital-based infant phototherapy solutions throughout Australia.

Frequently Asked Questions (FAQs) about the Australia Infant Phototherapy Device Market Report

1. What factors are driving the growth of the Australia Infant Phototherapy Device Market?

The market is growing due to increasing preterm births, rising incidence of neonatal jaundice, expanding neonatal intensive care infrastructure, and government investment in maternal and child healthcare. Adoption of advanced LED phototherapy systems, growing awareness of early diagnosis, and continuous technological innovation are further accelerating market expansion across Australia.

2. How are LED phototherapy devices improving neonatal jaundice treatment in Australia?

LED phototherapy devices provide higher irradiance, uniform light distribution, lower heat generation, and greater energy efficiency than conventional fluorescent systems. Their longer operational life, reduced maintenance needs, and improved treatment effectiveness help hospitals enhance patient safety, shorten treatment duration, and deliver better clinical outcomes for newborns with jaundice.

3. How are regulatory approvals supporting Australia's infant phototherapy device industry?

Regulatory approvals from the Therapeutic Goods Administration (TGA) are enabling the introduction of innovative phototherapy devices into the Australian healthcare system. Newly approved LED and fiber-optic phototherapy technologies expand treatment options for hospitals, encourage technology adoption, and improve the availability of advanced neonatal care equipment across the country.

4. What challenges are affecting the Australia infant phototherapy device market?

The market faces challenges including the high procurement and maintenance costs of advanced phototherapy systems and limited access to specialized neonatal care in rural and remote regions. Budget constraints, workforce shortages, and unequal healthcare infrastructure can delay equipment upgrades and restrict timely treatment for newborns requiring phototherapy.

5. How are Australia's hospitals contributing to demand for infant phototherapy devices?

Hospitals are the primary users of infant phototherapy devices due to routine neonatal jaundice screening and treatment. Investments in neonatal intensive care units, modernization of maternity wards, adoption of digital monitoring systems, and replacement of older fluorescent equipment with advanced LED technologies are driving sustained demand across public and private hospitals.

6. What technological trends are shaping the future of Australia's infant phototherapy device market?

Key trends include increasing adoption of LED-based phototherapy, portable and mobile treatment units, fiber-optic blanket systems, integrated irradiance monitoring, touchscreen controls, and compatibility with neonatal warmers. These innovations improve treatment efficiency, enhance infant comfort, support family-centered care, and strengthen neonatal healthcare services throughout Australia.

Market Segmentation

Light Source

• Fluorescent Lamps
• Light Emitting Diodes
• Quartz Halogen Lamps
• Gas Discharge Tubes

Configuration

• Mobile Device
• Fixed Device

End User

• Hospital
• Neonatal Clinics

States

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Australian Capital Territory
• Tasmania
• Northern Territory

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Ningbo David Medical Device Co., Ltd
• Koninklijke Philips N.V.
• General Electric Company
• Inapiration Healthcare Group Plc
• Drägerwerk AG & Co. KGaA
• Ibis Medical Equipment and Systems Pvt Ltd
• Weyer GmbH
• Natus Medical Incorporated